Aatec Medical GmbH has announced the start of its collaboration with the German Federal Agency for Disruptive Innovations (SPRIND), which will help advance the preclinical development of ATL-105.
Windtree Therapeutics Inc. has renewed its partnership with Chang Gung University to further research on SERCA2a, an important target for the company’s cardiovascular portfolio.
The European Chemicals Agency (ECHA) has contracted a consortium to conduct scientific studies on the reliability and relevance of new approach methodologies (NAMs) as alternatives to animal testing and to promote the use of such methods in the future.
Vaxxinity Inc. has announced a research collaboration with the University of Florida’s (UF) Center for Translational Research in Neurodegenerative Disease (CTRND) to support its work on the development of vaccines for neurodegenerative diseases.
Invitae Corp. has entered into a partnership with Bridgebio Pharma Inc. to advance genetics-based drug discovery for rare diseases. The goal of the collaboration is to generate new insights focused on genetic modifiers and the discovery of novel therapeutic targets for rare diseases and other unmet medical needs.
Ractigen Therapeutics Co. Ltd. has entered into a formal collaboration with University Medical Center Utrecht, affiliated with Utrecht University, to advance the development of small activating RNA (saRNA)-based treatments for a spectrum of intractable neurodevelopmental disorders.
Transcode Therapeutics Inc. has entered into a co-research agreement with Debiopharm SA that will bring together Transcode’s proprietary TTX delivery platform with Debiopharm’s expertise in targeted drug delivery to co-develop targeted nucleic acid therapeutics for cancer.
Synthekine Inc. has established a worldwide collaboration with Sanofi SA to develop and commercialize IL-10 receptor agonists for the treatment of inflammatory diseases.